Related Experiment Videos
11 beta-hydroxyandrostenedione in human amniotic fluid.
Experimental and Clinical Endocrinology
|December 1, 1990
Summary
11 beta-Hydroxyandrostene-3,17-dione, a potential marker for congenital adrenal hyperplasia diagnosis, was measured in amniotic fluid. Concentrations were established in pregnancies without endocrine disorders, providing a reference range.
Area of Science:
- Endocrinology
- Biochemistry
- Prenatal Diagnostics
Background:
- Congenital adrenal hyperplasia (CAH) requires early prenatal diagnosis.
- 11 beta-Hydroxyandrostene-3,17-dione is a potential biomarker for CAH.
- Establishing reference ranges in unaffected pregnancies is crucial.
Purpose of the Study:
- To determine the concentration of 11 beta-Hydroxyandrostene-3,17-dione in amniotic fluid from pregnancies without endocrine disorders.
- To establish reference values for this potential CAH marker.
Main Methods:
- Measurement of 11 beta-Hydroxyandrostene-3,17-dione in amniotic fluid samples.
- Analysis of 68 samples from women delivering healthy infants.
- Statistical analysis of concentration data.
Main Results:
- The average concentration of 11 beta-Hydroxyandrostene-3,17-dione was 0.96 +/- 0.31 nmol/l.
- Concentrations did not vary significantly with fetal sex.
- A slight, non-significant increase was observed with advancing pregnancy duration.
Conclusions:
- Reference ranges for 11 beta-Hydroxyandrostene-3,17-dione in normal pregnancies were established.
- These findings support its potential utility as a prenatal marker for CAH.
- Further studies are warranted to confirm its diagnostic value.